When was ARTHEx founded?

ARTHEx was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is ARTHEx located?

ARTHEx is headquartered in Valencia, Spain.

How many employees does ARTHEx have?

As of Jul 01, 2024, the latest employee count at ARTHEx is 14.

Is ARTHEx a funded company?

ARTHEx is a funded company, having raised a total of $93.6M across 9 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 2019.

When was the latest funding round of ARTHEx?

ARTHEx's latest funding was a $***** Series B round on Sep 17, 2025, with participation from 8 investors.

Where does ARTHEx rank among its competitors?

ARTHEx ranks 78th amongst 569 active competitors, of which 208 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was ARTHEx, which secured $40.6M in Sep, 2025.

Who are the top competitors of ARTHEx?

ARTHEx's top competitors include Sana Biotechnology, Spark Therapeutics and Fulcrum Therapeutics. Among them, ARTHEx secured the most recent funding round in September, 2025.

ARTHEx - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of oligonucleotide therapies for neuromuscular diseases. The company offers products that are involved in neuromuscular diseases, focusing on Myotonic Dystrophy. The company's lead candidate inhibits miRNAs from repressing MBNL1/2, to compensate for MBNL loss of function.

Website: www.arthexbiotech.com/
Social

Key Metrics

Founded Year

2018

Location

Valencia, Spain

Stage

Series B

Total Funding

$93.6M in 9 rounds

Latest Funding Round

Series B, Sep 17, 2025, $*****

Investors

Invivo Ventures & 12 more

Ranked

78^th among 569 active competitors

Employee Count

14 as on Jul 01, 2024

Similar Companies

Sana Biotechnology & 714 more

View ARTHEx's full profile

ARTHEx has raised a total funding of $93.6M over 9 rounds. Its first funding round was on Dec 2019. Its latest funding round was a Series B round on Sep 17, 2025 for $*****. 8 investors participated in its latest round. ARTHEx has 13 institutional investors.

Here is the list of recent funding rounds of ARTHEx:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 17, 2025	8007261	Series B	1206027	3049209	1859582	1977315
May 04, 2023	3496857	Series B	2958323	9631311	6034164	CDTI & 5 more
Mar 21, 2023	2668680	Grant (prize money)	9340637	2999671	4807293	European Investment Bank

Access funding benchmarks and valuations. Sign up today!

View details of ARTHEx's funding rounds and investors

The founders of ARTHEx are Ruben Artero and Beatriz Llamusi.

Here are the details of ARTHEx's key team members:

Ruben Artero: Co-Founder of ARTHEx.
Beatriz Llamusi: Co-Founder & CEO of ARTHEx.
Contact Info: 1 email address

View details of ARTHEx's Founder profiles and Board Members

ARTHEx's employee count trend

ARTHEx has 14 employees as of Jul 24. Here is ARTHEx's employee count trend over the years:

Uncover ARTHEx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ARTHEx include Sana Biotechnology, Spark Therapeutics and Fulcrum Therapeutics. Here is the list of Top 10 competitors of ARTHEx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Wellington & 6 others	74/100
3rd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
4th	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	70/100
5th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	70/100
6th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
7th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	70/100
8th	Entrada Therapeutics 2016, Boston (United States), Public	Developer of the biologics-based platform to treat rare diseases	$175M	5AM Ventures, Wellington & 11 others	69/100
9th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 9 others	69/100
10th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
78th	ARTHEx 2018, Valencia (Spain), Series B	Developer of oligonucleotide therapies for neuromuscular diseases	$93.6M	Columbus Venture Partners, Hadean Ventures ... & 11 others	57/100